Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Inclusion Criteria:

1. Participants must be able to understand and be willing to sign a written informed consent document;
2. Men and woman who are at least 18 years of age on the day of consenting to the study;
3. According to the WHO 2016 classification criteria, pathologically confirmed CD20+diffuse large B-cell lymphoma;
4. Patients with MYD88 and CD79A/B mutations or CD79B alone;
5. Relapse or progression after treatment with at least two prior therapies;
6. There is at least one measurable lesion, defined as a two-path measurable, intraductal lesion short neck \>1.5cm, extranodal lesion short diameter \>1.0cm;
7. Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
8. Blood routine examination meets the following criteria:

   Neutrophil count ≥ 1.0 x 109 / L; Platelet ≥ 75 x 109 / L; Hemoglobin ≥ 10.0 g / dL;
9. The main organ function meets the following criteria:

   Aspartate aminotransferase and alanine aminotransferase ≤ 2.0 times the upper limit of normal value; Bilirubin ≤ 2.0 mg / dL; Creatinine clearance rate ≥ 60 mL / min;
10. Must agree to effective contraception

Exclusion Criteria:

1. Transformed diffuse large B-cell lymphoma;
2. HBV DNA positive or HCV RNA positive;
3. Patient is known to have an uncontrolled active systemic infection;
4. Left ventricular ejection fraction \< 40%;
5. Previous autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, dry syndrome, ankylosing spondylitis, etc;
6. Immunosuppressive drugs are being or have been used in the past;
7. Known hypersensitivity to the study drug or any of its excipients;
8. There are other active malignant tumors that may interfere with this study requiring treatment;
9. Known history of human immunodeficiency virus (HIV) infection;
10. Previous autologous stem cell transplantation or allogeneic hematopoietic stem cell transplantation;
11. The investigator judges that the patient has other inappropriate circumstances.